Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2019

Aug 14, 2019

SELL
$2.19 - $3.4 $8,103 - $12,580
-3,700 Closed
0 $0
Q4 2018

Feb 14, 2019

BUY
$1.72 - $7.24 $6,364 - $26,788
3,700 New
3,700 $8,000

Others Institutions Holding ALT

About Altimmune, Inc.


  • Ticker ALT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,025,300
  • Market Cap $370M
  • Description
  • Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...
More about ALT
Track This Portfolio

Track Nordea Investment Management Ab Portfolio

Follow Nordea Investment Management Ab and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nordea Investment Management Ab, based on Form 13F filings with the SEC.

News

Stay updated on Nordea Investment Management Ab with notifications on news.